重组人血管内皮抑制素联合顺铂治疗非小细胞肺癌恶性胸腔积液疗效观察

目的观察重组人血管内皮抑制素（YH-16）联合顺铂对非小细胞肺癌（NSCLC）恶性胸腔积液的临床疗效和不良反应。方法将80例NSCLC合并胸腔积液患者随机分为2组,每组为40例。联合组胸腔内注入YH-16 30 mg,2次/周,同时给予顺铂40mg胸腔内注入,1次/周,连续3周;顺铂组采用顺铂40mg胸腔内注入,1次/周,连续3周。评价近期疗效、生活质量及不良反应。结果联合组RR为83.00%,顺铂组为48.00%（P〈0.01）。联合组生活质量改善有24例（80%）,顺铂组为15例（42.5%）（P〈0.01）。2组不良反应比较差异无统计学意义。结论 YH-16联合顺铂治疗NSCLC胸腔积液疗效显著,可明显改善患者的生活质量,且不良反应小。

Therapeutic observation of endostar combined with cisdiammi dichloride platinum on non-small cell lung cancer with malignant pleural effusion

Objective To evaluate the clinical efficacy and side effects of endostar（YH-16） combined with cisdiammi dichloride platinum（cDDP） in the treatment of non-small cell lung cancer（NSCLC） with malignant pleural effusion（MPE）.Methods Eighty NSCLC patients with pleural effusion were equally randomized into combination group（endostar combined with cDDP） and cDDP group.The combination group was performed intrapleural injection of YH-16（30mg,twice a week） and cDDP（40mg,once a week for 3 weeks）.The control group was only given intrapleural injection of cDDP（40 mg,once a week for 3 weeks）.The efficacy,quality of life（QOL）,safety and adverse events were evaluated.Results The recovery rate（RR） of the combination group was 83.00%,and 48% for the control group（P0.01）.Twenty-four（80%） patients in the combination group reported improved QOL,while there were only 15 patients（42.5%） in the control group（P0.01）.The differences of adverse events in both groups had no statistical significance.Conclusion Intrapleural injection of endostar combined with cDDP is a safe and feasible way to treat NSCLC with MPE.